Maha's, MS, MRA, CCRC, educational background is in Clinical Research Regulatory Affairs, Biotechnology and Life Sciences. At Penn Medicine, our goal is to bring new treatments and innovative approaches to improve patients’ lives.

Ms Dutt’s portfolio at the Office of Clinical Research includes navigating clinical research sites through the complex maze of resources we offer at Penn Medicine. This includes patient recruitment, training requirements, research application implementation and maintenance; and, most importantly facilitating patients and caregivers as they try to find the right trial for their needs.

Jillian Agnew, RN, CCRC, is the Senior Clinical Research Nurse at St. Johns Center for Clinical Research in St. Augustine, Florida. She received her Certification in Clinical Research (CCRC) in 2021 and is currently the lead study nurse for all cardiovascular trials at her site.

Prior to research, Ms Agnew worked in multiple areas of nursing including Emergency, Home Health, Public Health and Trauma Critical Care at the University of Maryland R. Adams Cowley Shock Trauma Center in Baltimore, Maryland. Critical care will always be near and dear to her heart, but research has quickly become her favorite kind of nursing. “I really enjoy the relationships I develop with my research patients. I love seeing pictures of their kids, grandchildren, pets, etc. It shows how much they appreciate the amount of time you are investing in them. I also love that I have a career that brings me so much job satisfaction. Every day, I feel like I am making a difference and working towards a larger goal for the greater good.”

Outside of work, Ms Agnew and her family enjoy geocaching, game nights with friends and spending time at the beach.

Yaping Shou, M.D., Ph.D., is the Founder and CEO of Wells Therapeutics, Inc. and a Venture Partner at Lilly Asia Ventures (LAV). Yaping has over 20 years of global clinical development experience in both pharma (GlaxoSmithKline, Novartis, and Takeda) and biotech (Trillium) companies. Yaping was the chief medical officer of Trillium Therapeutics, and prior to that, the executive medical director with Takeda Pharmaceuticals. She has made critical contributions to the development and approval of multiple oncology drugs including lapatinib, pazopanib, nilotinib, sonidegib, and ixazomib. She also led significant clinical progress at Trillium in recent years which formed the strong basis for Pfizer's $2.3b acquisition of Trillium in 2021. In her current role at LAV, Yaping leverages her development expertise to support investment decisions. She also provides strategic guidance to help businesses achieve clinical development success, financial growth, and optimal organizational performance. She founded Wells Therapeutics Inc. in June 2022 with the goal to accelerate globalization of regionally sourced therapeutics for the benefit of patients worldwide. Yaping holds a MD degree from Zhejiang University School of Medicine and a PhD degree in cellular and molecular biology from Drexel University. She also received post-doctoral fellowship training at the Genetic Branch of NCI. As a female executive, Yaping graduated from a 12-month woman leadership program for high-potential women led by WOMAN Unlimited, Inc., and received leadership training at SAID Business School of Oxford and MIT Sloan School of Management.

Neely Mozaffarian, MD, PhD, is the chief medical officer at Atomwise, a privately held company based in San Francisco that is developing novel, AI-driven therapies for autoimmune and autoinflammatory diseases. Prior to Atomwise, Dr. Mozaffarian was CMO at GentiBio, Pathway Area Stronghold Leader and VP Immunology at Janssen/J&J, and led teams in global drug development for large and small molecules across clinical trial phases 1-4 at Ichnos/Glenmark, Gilead Sciences, Eli Lilly & Co., and AbbVie/Abbott. She received her MD and PhD in Microbiology and Immunology from Albert Einstein College of Medicine in NY, followed by Internal Medicine residency and Rheumatology fellowship at the University of Washington in Seattle, where she performed research on immune abnormalities in systemic lupus erythematosus and other autoimmune diseases.

Emily Adney-Holt, PhD, serves as a Technical Sales Specialist at Lunaphore Technologies. Within the Lunaphore commercial team, Dr Adney-Holt collaborates with scientists, delving into the intricacies of their instruments. She provides valuable support to researchers in implementing experiments that harness the full potential of Lunaphore's cutting-edge technology for advancing spatial biology studies.

Drawing on her extensive background as a genome scientist, biophysicist, and molecular biologist, Dr Adney-Holt is deeply committed to propelling scientific understanding in cellular biology to new heights.

Dr Adney-Holt earned her PhD in Human Genetics from The Johns Hopkins University School of Medicine and holds a master's in Molecular Biophysics from Johns Hopkins University. Her academic journey reflects a strong foundation in both genetics and biophysics, contributing to her multifaceted expertise in the field.

April Lewis is a 25-year veteran of clinical R&D, with proven success leading global teams focused on innovating and disrupting clinical trial operations. Ms Lewis has served as a key leader on large transformational initiatives including the Quintiles/IMS merger, and GSK’s “Future Ready” Vx/Rx integration strategy. Currently, Ms Lewis leads Innovative Health at Johnson and Johnson, responsible for the development and scaling of novel and innovative solutions for use across Global Development. Ms Lewis holds an MS in Organizational Psychology. Ms Lewis is a proud girl mom, with 3 college-aged daughters.